L. Azoulay

First name
L.
Last name
Azoulay
Rouette, J., McDonald, E. G., Schuster, T., Matok, I., Brophy, J. M., & Azoulay, L. (2023). Thiazide Diuretics and Risk of Colorectal Cancer: A Population-Based Cohort Study. Am J Epidemiol. http://doi.org/10.1093/aje/kwad171
View
Abrahami, D., D'Andrea, E., Yin, H., Kim, S. C., Paik, J. M., Wexler, D., et al. (2023). Contemporary trends in the utilization of second-line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom. Diabetes Obes Metab. http://doi.org/10.1111/dom.15196
View
Ayele, H. T., Reynier, P., Azoulay, L., Platt, R. W., Cabaussel, J., Benayoun, S., & Filion, K. B. (2023). The Cardiovascular Safety of 5-Alpha-Reductase Inhibitors Among Men with Benign Prostatic Hyperplasia: A Population-Based Cohort Study. Am J Med. http://doi.org/10.1016/j.amjmed.2023.06.021
View
Doherty, N., Cardwell, C. R., Murchie, P., Hill, C., Azoulay, L., & Hicks, B. (2023). 5-Alpha Reductase Inhibitors and Risk of Kidney and Bladder Cancers in Men with Benign Prostatic Hyperplasia: A Population-Based Cohort Study. Cancer Epidemiol Biomarkers Prev. http://doi.org/10.1158/1055-9965.epi-22-1109
View
Abrahami, D., Pradhan, R., Yin, H., Yanofsky, R., McDonald, E. G., Bitton, A., & Azoulay, L. (2023). Proton pump inhibitors and the risk of inflammatory bowel disease: population-based cohort study. Gut. http://doi.org/10.1136/gutjnl-2022-328866
View
Rouette, J., McDonald, E. G., Schuster, T., Brophy, J. M., & Azoulay, L. (2022). Dihydropyridine Calcium Channel Blockers and Risk of Pancreatic Cancer: A Population-Based Cohort Study. J Am Heart Assoc, 11, e026789. http://doi.org/10.1161/jaha.122.026789
View
Pradhan, R., Lu, S., Yin, H., H. Y. Yu, O., Ernst, P., Suissa, S., & Azoulay, L. (2022). Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study. Bmj, 379, e071380. http://doi.org/10.1136/bmj-2022-071380
View
Suissa, K., Schneeweiss, S., Douros, A., Yin, H., Patorno, E., & Azoulay, L. (2022). Obesity as a modifier of the cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes. Diabetes Res Clin Pract, 192, 110094. http://doi.org/10.1016/j.diabres.2022.110094
View
Cao, T. X. D., Filliter, C., Montastruc, F., H. Y. Yu, O., Fergusson, E., Rej, S., et al. (2022). Selective serotonin reuptake inhibitors and the risk of type 2 diabetes mellitus in youths. J Affect Disord, 318, 231-237. http://doi.org/10.1016/j.jad.2022.08.094
View
Abrahami, D., Tesfaye, H., Yin, H., Vine, S., Hicks, B., H. Y. Yu, O., et al. (2022). Sodium-Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Bladder Cancer: An International Multisite Cohort Study. Diabetes Care. http://doi.org/10.2337/dc22-1174
View